PRIME MEDICINE, INC. COMMON STOCK reports a Return on Equity (ROE) of -258.64%.

What is PRME's dividend yield?

PRIME MEDICINE, INC. COMMON STOCK offers a dividend yield of 0.00%.

What is PRME's Deepscope Quality Score?

Deepscope rates PRME's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PRME?

Deepscope's AI Timing Score for PRME is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PRME belong to?

PRIME MEDICINE, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

หุ้น PRME (NASDAQ) | PRIME MEDICINE, INC. COMMON STOCK – วิเคราะห์โดย Deepscope

Stock Check ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.
(Price: 2026-06-05 | FS: 2026-03-31)

PRME

PRIME MEDICINE, INC. COMMON STOCK

US:NASDAQ STOCK Healthcare >> Biotechnology News 93

USD 3.06

-0.41 (-11.82%) Day Change

Watchlist Portfolio Compare Chart

0.11

D/E

-258.6%

ROE

-67.3%

ROA

0.00%

Div Yield

PRIME MEDICINE, INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.06 Price -0.41 (-11.82%) Day Change	NEWS SCORE: 93

PRME มีคุณภาพโดยรวมไม่ดี ( คะแนนปัจจัยพื้นฐาน = 31) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ในปีก่อน เป็นลบ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ลดลงอย่างมีนัยยะสำคัญ
อัตราการเติบโตของอัตราผลตอบแทนสินทรัพย์(ROA) ปัจจุบันต่ำกว่าเกณฑ์
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร ไม่ดี , ...

ปัจจัยทางคุณภาพ

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	93
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.06
PBV / Sector	7.39 / 4.63
Earning Per Share	-1.07

PE / Sector	N/A / 17.43
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	9.20 M
Average 1W Daily Value	11.30 M GREAT

ปัจจัยทางเทคนิค

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

สุขภาพทางการเงิน

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ประสิทธิภาพการทำกำไร

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-4,917.55 / 449.48
NPM Average (%) / Sector	-4,541.21 / -1,506.49
NPM Change Average (%) / Sector	N/A / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-67.31 / 30.58
ROA Average (%) / Sector	-65.57 / -347.17
ROA Change Average (%) / Sector	42.64 / 5,125.52 GREAT
ROE (%) / Sector	-258.64 / -3.58
ROE Average (%) / Sector	-148.07 / 40.65
ROE Change Average (%) / Sector	89.50 / 2,109.80 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

ผลตอบแทนต่อผู้ถือหุ้น

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

รายละเอียดการจดทะเบียน

Analyze Date	2026-06-06 09:09:07
Symbol	PRME
Name	PRIME MEDICINE, INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	180.62 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	567.14 / 8,857.28

ข่าว, ประมาณการ, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 60 First Street, Cambridge, MA, United States, 02141

Phone: 617 465 0013

Website: https://primemedicine.com

Employees: 146

Sector: Healthcare >> Biotechnology

Description: Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.